Anti-CD2 monoclonal antibody and tacrolimus in adult liver transplantation.
- Lerut, Jan
- Vanthuyne, Vincent
- Mathijs, Jules
- Lemaire, Julien
- Talpe, Stéphanie
- Roggen, Francine
- Ciccarelli, Olga
- Zuckermann, Michele
- Goffette, Pierre
- Hope, James
- Gianello, Pierre
- Bazin, Hervé
- Cornet, Anne
- Rahier, Jacques
- Latinne, Dominique
DOIAbstract
BACKGROUND: Blockade of costimulation and adhesion signaling is an attractive approach to interfere with graft rejection METHODS: Between January 1997 and May 1999, forty adults having benign liver diseases were included in a prospective, randomized study comparing tacrolimus plus low-dose short-term steroids without (n=20, TAC group) or with a 10-day course of antihuman CD2 monoclonal antibody (n=20, BTI group). RESULTS: At day 7, histological rejection expressed by mean Banff scores (2.3+/-1.6 vs. 5.4+/-1.6 in the TAC group; Por=6) (0 vs. 10 [50%] in the TAC group; P<0.001) were significantly lower in the BTI group. Rejection was treated in 10% (two patients) of BTI patients during the first 3 months and in 15% during the whole follow-up ...
Add to ORKG